Voyager Therapeutics, Inc. Research and Development Expense
Voyager Therapeutics, Inc. (VYGR) reported Research and Development Expense of $22.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Voyager Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $22.04M, a 29.65% decline year-over-year.
- Voyager Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $24.60M, a 21.96% decline year-over-year.
- Voyager Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $35.95M, a 1.04% increase year-over-year.
- Voyager Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $35.87M, a 18.60% increase year-over-year.
- Voyager Therapeutics, Inc. research and development expense for fiscal 2025 was $134.67M, a 5.74% increase from fiscal 2024.
- Voyager Therapeutics, Inc. research and development expense for fiscal 2024 was $127.37M, a 38.19% increase from fiscal 2023.
- Voyager Therapeutics, Inc. research and development expense for fiscal 2023 was $92.17M, a 51.69% increase from fiscal 2022.
- Voyager Therapeutics, Inc. research and development expense for fiscal 2022 was $60.76M, a 17.65% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.04M 10-Q · filed 2026-08-06 | $46.64M 10-Q · filed 2026-08-06 | $82.59M derived: sum of 3 quarters · filed 2026-08-06 | $118.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $24.60M 10-Q · filed 2026-05-07 | $60.55M derived: sum of 2 quarters · filed 2026-05-07 | $96.42M derived: sum of 3 quarters · filed 2026-05-07 | $127.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $35.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $71.82M derived: sum of 2 quarters · filed 2026-03-09 | $103.15M derived: sum of 3 quarters · filed 2026-08-06 | $134.67M 10-K · filed 2026-03-09 |
| 2025-09-30 | $35.87M 10-Q · filed 2025-11-10 | $67.20M derived: sum of 2 quarters · filed 2026-08-06 | $98.72M 10-Q · filed 2025-11-10 | $134.31M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $31.33M 10-Q · filed 2026-08-06 | $62.86M 10-Q · filed 2026-08-06 | $98.44M derived: sum of 3 quarters · filed 2026-08-06 | $128.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $31.53M 10-Q · filed 2026-05-07 | $67.11M derived: sum of 2 quarters · filed 2026-05-07 | $97.35M derived: sum of 3 quarters · filed 2026-05-07 | $131.80M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $35.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $65.82M derived: sum of 2 quarters · filed 2026-03-09 | $100.28M derived: sum of 3 quarters · filed 2026-03-09 | $127.37M 10-K · filed 2026-03-09 |
| 2024-09-30 | $30.24M 10-Q · filed 2025-11-10 | $64.69M derived: sum of 2 quarters · filed 2025-11-10 | $91.78M 10-Q · filed 2025-11-10 | $117.54M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $34.45M 10-Q · filed 2025-08-06 | $61.54M 10-Q · filed 2025-08-06 | $87.30M derived: sum of 3 quarters · filed 2026-03-09 | $113.16M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $27.09M 10-Q · filed 2025-05-06 | $52.85M derived: sum of 2 quarters · filed 2026-03-09 | $78.71M derived: sum of 3 quarters · filed 2026-03-09 | $100.70M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $25.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $51.62M derived: sum of 2 quarters · filed 2026-03-09 | $73.60M derived: sum of 3 quarters · filed 2026-03-09 | $92.17M 10-K · filed 2026-03-09 |
| 2023-09-30 | $25.86M 10-Q · filed 2024-11-12 | $47.85M derived: sum of 2 quarters · filed 2024-11-12 | $66.42M 10-Q · filed 2024-11-12 | $80.97M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $21.98M 10-Q · filed 2024-08-06 | $40.55M 10-Q · filed 2024-08-06 | $55.10M derived: sum of 3 quarters · filed 2025-03-11 | $74.44M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $18.57M 10-Q · filed 2024-05-13 | $33.12M derived: sum of 2 quarters · filed 2025-03-11 | $52.46M derived: sum of 3 quarters · filed 2025-03-11 | $64.98M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $14.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $33.89M derived: sum of 2 quarters · filed 2025-03-11 | $46.41M derived: sum of 3 quarters · filed 2025-03-11 | $60.76M 10-K · filed 2025-03-11 |
| 2022-09-30 | $19.34M 10-Q · filed 2023-11-06 | $31.86M derived: sum of 2 quarters · filed 2023-11-06 | $46.21M 10-Q · filed 2023-11-06 | $60.23M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $12.53M 10-Q · filed 2023-08-03 | $26.88M 10-Q · filed 2023-08-03 | $40.90M derived: sum of 3 quarters · filed 2024-02-28 | $58.81M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $14.35M 10-Q · filed 2023-05-09 | $28.37M derived: sum of 2 quarters · filed 2024-02-28 | $46.28M derived: sum of 3 quarters · filed 2024-02-28 | $65.79M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $14.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $31.93M derived: sum of 2 quarters · filed 2024-02-28 | $51.44M derived: sum of 3 quarters · filed 2024-02-28 | $73.79M 10-K · filed 2024-02-28 |
| 2021-09-30 | $17.91M 10-Q · filed 2022-11-08 | $37.42M derived: sum of 2 quarters · filed 2022-11-08 | $59.77M 10-Q · filed 2022-11-08 | $81.76M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $19.50M 10-Q · filed 2022-08-04 | $41.85M 10-Q · filed 2022-08-04 | $63.85M derived: sum of 3 quarters · filed 2023-03-07 | $88.89M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $22.35M 10-Q · filed 2022-05-04 | $44.34M derived: sum of 2 quarters · filed 2023-03-07 | $69.38M derived: sum of 3 quarters · filed 2023-03-07 | $98.80M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $22.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $47.03M derived: sum of 2 quarters · filed 2023-03-07 | $76.46M derived: sum of 3 quarters · filed 2023-03-07 | $108.75M 10-K · filed 2023-03-07 |
| 2020-09-30 | $25.04M 10-Q · filed 2021-11-02 | $54.46M derived: sum of 2 quarters · filed 2021-11-02 | $86.76M 10-Q · filed 2021-11-02 | $123.31M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | $29.42M 10-Q · filed 2021-08-09 | $61.72M 10-Q · filed 2021-08-09 | $98.27M derived: sum of 3 quarters · filed 2022-03-08 | $128.04M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | $32.29M 10-Q · filed 2021-05-10 | $68.84M derived: sum of 2 quarters · filed 2022-03-08 | $98.62M derived: sum of 3 quarters · filed 2022-03-08 | $127.20M derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | $36.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $66.33M derived: sum of 2 quarters · filed 2022-03-08 | $94.90M derived: sum of 3 quarters · filed 2022-03-08 | $119.73M 10-K · filed 2022-03-08 |
| 2019-09-30 | $29.78M 10-Q · filed 2020-11-09 | $58.35M derived: sum of 2 quarters · filed 2020-11-09 | $83.18M 10-Q · filed 2020-11-09 | $100.10M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $28.58M 10-Q · filed 2020-08-10 | $53.41M 10-Q · filed 2020-08-10 | $70.32M derived: sum of 3 quarters · filed 2021-02-25 | $86.95M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $24.83M 10-Q · filed 2020-05-06 | $41.74M derived: sum of 2 quarters · filed 2021-02-25 | $58.38M derived: sum of 3 quarters · filed 2021-02-25 | $74.88M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $16.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $33.55M derived: sum of 2 quarters · filed 2021-02-25 | $50.05M derived: sum of 3 quarters · filed 2021-02-25 | $64.91M 10-K · filed 2021-02-25 |
| 2018-09-30 | $16.63M 10-Q · filed 2019-11-06 | $33.14M derived: sum of 2 quarters · filed 2019-11-06 | $47.99M 10-Q · filed 2019-11-06 | $61.32M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-06-30 | $16.51M 10-Q · filed 2019-08-09 | $31.36M 10-Q · filed 2019-08-09 | $44.69M derived: sum of 3 quarters · filed 2020-03-03 | $64.25M derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-03-31 | $14.85M 10-Q · filed 2019-05-07 | $28.18M derived: sum of 2 quarters · filed 2020-03-03 | $47.74M derived: sum of 3 quarters · filed 2020-03-03 | $63.04M derived: sum of 4 quarters · filed 2020-03-03 |
| 2017-12-31 | $13.33M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $32.89M derived: sum of 2 quarters · filed 2020-03-03 | $48.19M derived: sum of 3 quarters · filed 2020-03-03 | $62.26M 10-K · filed 2020-03-03 |
| 2017-09-30 | $19.56M 10-Q · filed 2018-11-07 | $34.86M derived: sum of 2 quarters · filed 2018-11-07 | $48.93M 10-Q · filed 2018-11-07 | $61.66M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $15.30M 10-Q · filed 2018-08-07 | $29.37M 10-Q · filed 2018-08-07 | $42.09M derived: sum of 3 quarters · filed 2019-02-26 | $52.40M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $14.07M 10-Q · filed 2018-05-10 | $26.80M derived: sum of 2 quarters · filed 2019-02-26 | $37.10M derived: sum of 3 quarters · filed 2019-02-26 | $47.59M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $12.72M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $23.03M derived: sum of 2 quarters · filed 2019-02-26 | $33.52M derived: sum of 3 quarters · filed 2019-02-26 | $42.25M 10-K · filed 2019-02-26 |
| 2016-09-30 | $10.31M 10-Q · filed 2017-11-02 | $20.79M derived: sum of 2 quarters · filed 2017-11-02 | $29.53M 10-Q · filed 2017-11-02 | $38.74M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $10.48M 10-Q · filed 2017-08-08 | $19.22M 10-Q · filed 2017-08-08 | $28.44M derived: sum of 3 quarters · filed 2018-03-14 | $34.92M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $8.73M 10-Q · filed 2017-05-09 | $17.95M derived: sum of 2 quarters · filed 2018-03-14 | $24.43M derived: sum of 3 quarters · filed 2018-03-14 | $30.89M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $9.22M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $15.70M derived: sum of 2 quarters · filed 2018-03-14 | $22.16M derived: sum of 3 quarters · filed 2018-03-14 | $27.68M 10-K · filed 2018-03-14 |
| 2015-09-30 | $6.48M 10-Q · filed 2016-11-10 | $12.94M derived: sum of 2 quarters · filed 2016-11-10 | $18.46M 10-Q · filed 2016-11-10 | $21.42M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $6.46M 10-Q · filed 2016-08-11 | $11.98M 10-Q · filed 2016-08-11 | $14.94M derived: sum of 3 quarters · filed 2017-03-15 | $17.34M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $5.52M 10-Q · filed 2016-05-12 | $8.48M derived: sum of 2 quarters · filed 2017-03-15 | $10.88M derived: sum of 3 quarters · filed 2017-03-15 | |
| 2014-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $5.36M derived: sum of 2 quarters · filed 2017-03-15 | $8.90M 10-K · filed 2017-03-15 | |
| 2014-09-30 | $2.40M 10-Q · filed 2015-12-17 | $5.94M 10-Q · filed 2015-12-17 | ||
| 2013-12-31 | $2.32M 10-K · filed 2016-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |